Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care

Medtronic plc has finalized its acquisition of Scientia Vascular for $550 million, a strategic move aimed at enhancing its neurovascular care offerings. The deal, announced on June 12, 2026, is subject to customary adjustments and may include potential undisclosed earn-out and milestone payments. This acquisition is expected to be minimally dilutive to Medtronic's adjusted earnings per share (EPS) in fiscal year 2027 and accretive thereafter.

Scientia Vascular, based in Salt Lake City, specializes in developing access products for complex neurovascular conditions, including a portfolio of guidewires and catheters. These products are designed to improve navigability through the intricate cerebral vasculature, which is essential for timely and effective stroke treatment. Stroke remains a leading cause of death and disability globally, making the need for innovative solutions in this area critical. By integrating Scientia's technologies with its existing neurovascular product suite, Medtronic aims to streamline procedural workflows and enhance the overall efficiency of treatment.

The acquisition aligns with Medtronic's ongoing strategy to strengthen its core business through targeted investments in high-growth opportunities. Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, emphasized that the addition of Scientia's technologies will support physicians in performing complex procedures with greater ease and confidence. This integration is expected to facilitate the delivery of care to a larger patient population, addressing the urgent need for advancements in neurovascular treatment.

The broader market dynamics indicate a growing demand for innovative medical devices in the neurovascular sector, driven by an increasing prevalence of stroke and other neurovascular diseases. As healthcare providers seek to enhance patient outcomes, companies like Medtronic are poised to capitalize on this trend by offering comprehensive solutions that address the challenges faced by clinicians in this specialized field.

Overall, the acquisition of Scientia Vascular represents a significant step for Medtronic in reinforcing its leadership position in the neurovascular market. By leveraging Scientia's advanced access technologies, Medtronic is not only enhancing its product offerings but also positioning itself to meet the evolving needs of healthcare providers and patients in an increasingly competitive landscape.